Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France
Guillaume Morel

, Guillaume Mulier, Etienne Ghrenassia, Moustafa Abdel Nabey, Yacine Tandjaoui, Achille Kouatchet, Laura Platon, Frédéric Pène, Anne-Sophie Moreau, Amelie Seguin, Damien Contou, Romain Sonneville, David Rousset, Muriel Picard, Guillaume Dumas, Djamel Mokart, Bruno Megarbane, Guillaume Voiriot, Isabelle Oddou, Elie Azoulay, Lucie Biard, and Lara Zafrani
Author affiliations: Hautepierre Hospital—University Medical Center, Strasbourg, France (G. Morel); Hospital Saint Louis, APHP, Paris, France (G. Morel, G. Mulier, E. Ghrenassia, M.A. Nabey, E. Azoulay, L. Biard, L. Zafrani); Hospital Avicenne, Bobigny, France (Y. Tandjaoui); Teaching Hospital, Angers, France (A. Kouatchet); Lapeyronie University Hospital, Montpellier, France (L. Platon); Hospital Cochin, APHP, Paris (F. Pène); Salengro Hospital, Lille, France (A.-S. Moreau); University Hospital, Nantes, France (A. Seguin); Victor Dupouy Hospital, Argenteuil, France (D. Contou); Hospital Bichat, APHP, Paris (R. Sonneville); University Teaching Hospital, Toulouse, France (D. Rousset),; Institut Universitaire du Cancer—Oncopole, Toulouse (M. Picard); Hospital Saint Antoine, APHP, Paris (G. Dumas); Paoli-Calmettes Institute, Marseille, France (D. Mokart); Hospital Lariboisiere, APHP, Paris (B. Megarbane); Hospital Tenon, APHP, Paris (G. Voiriot); University Medical Center, Strasbourg (I. Oddou); INSERM U976, Paris (L. Zafrani)
Main Article
Table 1
Global characteristics of patients with Clotristridium bacteremia, France*
Characteristic |
Baseline population, n = 135 |
Survived, n -= 65
|
Died in ICU, n = 70 |
Age |
|
|
|
Age at diagnosis, median (IQR) |
64 (51–75) |
62 (50–70) |
66 (54–79) |
Age at diagnostic >65 y
|
67 (50)
|
27 (42)
|
40 (57)
|
Sex |
|
|
|
|
M |
81 (60) |
43 (66) |
38 (54) |
F
|
54 (40)
|
22 (33)
|
32 (46)
|
All underlying conditions |
130 (96) |
62 (95) |
68 (97) |
Diabetes mellitus |
34 (26) |
19 (31) |
15 (22) |
Neoplasm |
34 (26) |
17 (27) |
17 (25) |
Chronic obstructive pulmonary disease |
33 (25) |
15 (24) |
18 (26) |
Alcoholism |
26 (20) |
11 (18) |
15 (22) |
Heart failure |
26 (20) |
9 (15) |
17 (25) |
Hematological malignancy |
19 (15) |
7 (11) |
12 (18) |
Liver cirrhosis |
13 (10) |
4 (6) |
9 (13) |
Chronic renal failure |
10 (8) |
8 (13) |
2 (3) |
Arteriopathy |
9 (7) |
3 (5) |
6 (9) |
Autoimmune diseases |
7 (5) |
4 (6) |
3 (4) |
HIV
|
1 (1)
|
0
|
1 (1)
|
Other predisposing conditions |
|
|
|
Surgery or trauma in the previous 15 d |
13 (10) |
10 (16) |
3 (4) |
Digestive surgery |
10 (77) |
7 (70) |
3 (100) |
Trauma
|
3 (23)
|
3 (30)
|
0
|
Immunosuppressive agents |
|
|
|
Patients receiving Immunosuppressive agents |
38 (28) |
18 (28) |
20 (29) |
Steroids |
20 (53) |
9 (50) |
11 (55) |
Chemotherapy |
20 (53) |
9 (50) |
11 (55) |
Immunosuppressive drugs |
10 (26) |
6 (33)
|
4 (20) |
Main Article
Page created: May 27, 2021
Page updated: June 18, 2021
Page reviewed: June 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.